this study alone will take us to $100+
wow three incredible reports since Fri Close !!
Yahoo Finance 12/8/13
Gilead Announces Pivotal Phase 2 Data for Idelalisib in Refractory Indolent Non-Hodgkin’s Lymphoma
Gilead Announces Interim Phase 2 Results for GS-9973 in Previously Treated Chronic Lymphocytic Leukemia
U.S. Food and Drug Administration Approves Gileadâ€™s Sovaldiâ„¢ (Sofosbuvir) for the Treatment of Chronic Hepatitis C
Do the DD.
Wall Street Journal
How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application?
Acadia said the FDA agreed the company had enough compelling data for pimavanserin, its lead drug candidate proposed for treating for Parkinson’s disease psychosis.The FDA usually requires at least two successful late-stage trials, but will accept a single trial under certain circumstances, such as a drug that satisfies an unmet medical need
yes they do that's why there are SEC filing dummy
Nokia Unlocks Significant Value With Microsoft Deal
Trefis Team , Contributor
Nokia’s shareholders will be one big happy bunch. Not only has the Finnish handset maker succeeded inoffloading its handset business, an asset its shareholders were assigning very little value to until recently, but it also pocketed a hefty windfall in its deal with Microsoft.
In an agreement announced Monday, Nokia NOK +3% has agreed to sell its handset business to Microsoft for a total of $5 billion in cash. To sweeten the deal further, Nokia’s lucrative patent portfolio isn’t part of this transaction. Instead, Nokia will grant Microsoft MSFT +0.13% access to its patents for 10 years for another $2.2 billion in cash. Moreover, since the patent arrangement is non-exclusive, Nokia is free to add other patent licensees in this period as well.
MNKD News - Seeking Alpha Marlet Currents 8/14/13 JMP downgrades the shares to Market Perform from Market Outperform perhaps because the most obvious near-term catalyst is passed.( You can also go togoogle and find this.)
JMP Securities Boosts BIOD Price Target to $9 Analyst Rating Network Updated 8/16/13